Jenthera Therapeutics

Jenthera Therapeutics is a preclinical gene-editing biotechnology company leveraging its non-viral, non-lipid direct protein delivery CRISPR platform to develop breakthrough therapeutics in the field of oncology. Our platform directly delivers CRISPR ribonucleoprotein (RNP) in the form of biologics, minimizing toxicity, off-target effects, immunogenicity, and costly manufacturing expenses. Jenthera's platform technology can target various cells and tissues, suggesting new possibilities in the field of gene editing.